Treatment of Advanced Gastrointestinal Tumors With Albumin Taxol
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03977077|
Recruitment Status : Not yet recruiting
First Posted : June 6, 2019
Last Update Posted : June 6, 2019
|Condition or disease||Intervention/treatment||Phase|
|Advanced Gastrointestinal Tumors||Drug: Albumin binding taxol||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Retrospective Clinical Study on the Efficacy and Safety of Injection Taxol (Albumin Binding Type) in the Treatment of Patients With Advanced Gastrointestinal Tumors|
|Estimated Study Start Date :||June 1, 2019|
|Estimated Primary Completion Date :||October 31, 2019|
|Estimated Study Completion Date :||October 31, 2020|
|Experimental: Albumin binding taxol||
Drug: Albumin binding taxol
125mg/m2, d1, 8, intravenous infusion for 30min, 1 cycle every 3 weeks;Other combined chemotherapy drugs and drug doses shall be administered by clinicians according to the guidelines and the actual situation of clinical patients.
- Progression free survival (PFS) [ Time Frame: up to 2 year ]Progression free survival (PFS) is the time between the onset of treatment and the observation of disease progression or death from any cause.
- Objective remission rate (ORR) [ Time Frame: up to 2 year ]Defined as the proportion of patients with a documented complete response, and partial response (CR+PR)
- Overall survival [ Time Frame: up to 2 year ]The Overall survival (OS) is defined as the date from random grouping to death from any cause.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03977077
|Contact: Xifang Houfirstname.lastname@example.org|
|Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital|
|Zhengzhou, Henan, China, 450008|